Integra LifeSciences Holdings Corporation (IART) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $12.62 (-1.64%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 15, 2026 | Richard Newitter | Truist Financial | $12.00 | -4.9% |
| Oct 7, 2024 | Ryan Zimmerman | BTIG | $20.00 | +58.5% |
| Jul 30, 2024 | Richard Newitter | Truist Financial | $26.00 | +106.0% |
| Jul 30, 2024 | Joanne Wuensch | Citigroup | $23.00 | +82.3% |
| Jul 29, 2024 | Ryan Zimmerman | BTIG | $22.00 | +74.3% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $32.00 | +153.6% |
| May 7, 2024 | Richard Newitter | Truist Financial | $25.00 | +98.1% |
| May 7, 2024 | David Turkaly | JMP Securities | $40.00 | +217.0% |
| May 6, 2024 | Vik Chopra | Wells Fargo | $25.00 | +98.1% |
| Oct 26, 2022 | Matt O'Brien | Piper Sandler | $50.00 | +296.2% |
| Jul 28, 2022 | FY22 EPS | Piper Sandler | $55.00 | +335.8% |
| May 20, 2021 | Anthony Petrone | Jefferies | $86.00 | +581.5% |
| Apr 29, 2021 | Shagun Singh Chadha | RBC Capital | $74.00 | +486.4% |
| Apr 29, 2021 | Larry Biegelsen | Wells Fargo | $74.00 | +486.4% |
Top Analysts Covering IART
IART vs Sector & Market
| Metric | IART | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.12 | 2.25 | 2.41 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +25.2% | +153002.0% | +21.5% |
| P/E Ratio | -1.60 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.65B | $1.67B | $1.68B | 7 |
| 2027-03-31 | $393M | $395M | $397M | 3 |
| 2027-06-30 | $440M | $442M | $444M | 3 |
| 2027-09-30 | $432M | $434M | $436M | 3 |
| 2027-12-31 | $465M | $466M | $469M | 3 |
| 2028-03-31 | $410M | $412M | $414M | 2 |
| 2028-06-30 | $461M | $463M | $465M | 2 |
| 2028-09-30 | $455M | $457M | $459M | 2 |
| 2028-12-31 | $484M | $486M | $488M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.33 | $2.35 | $2.37 | 5 |
| 2027-03-31 | $0.52 | $0.52 | $0.53 | 1 |
| 2027-06-30 | $0.64 | $0.64 | $0.64 | 1 |
| 2027-09-30 | $0.66 | $0.66 | $0.67 | 1 |
| 2027-12-31 | $0.79 | $0.79 | $0.79 | 1 |
| 2028-03-31 | $0.57 | $0.58 | $0.58 | 2 |
| 2028-06-30 | $0.76 | $0.76 | $0.77 | 2 |
| 2028-09-30 | $0.80 | $0.80 | $0.81 | 2 |
| 2028-12-31 | $0.96 | $0.96 | $0.97 | 2 |
Frequently Asked Questions
What is the analyst consensus for IART?
The consensus among 16 analysts covering Integra LifeSciences Holdings Corporation (IART) is Hold with an average price target of $19.40.
What is the highest price target for IART?
The highest price target for IART is $86.00, set by Anthony Petrone at Jefferies on 2021-05-20.
What is the lowest price target for IART?
The lowest price target for IART is $12.00, set by Richard Newitter at Truist Financial on 2026-04-15.
How many analysts cover IART?
16 analysts have issued ratings for Integra LifeSciences Holdings Corporation in the past 12 months.
Is IART a buy or sell right now?
Based on 16 analyst ratings, IART has a consensus rating of Hold (3.12/5) with a +25.2% upside to the consensus target of $19.40.
What are the earnings estimates for IART?
Analysts estimate IART will report EPS of $2.35 for the period ending 2026-12-31, with revenue estimated at $1.67B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.